research use only

Molnupiravir (EIDD-2801) SARS-CoV inhibitor

Cat.No.S8969

Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19.
Molnupiravir (EIDD-2801) SARS-CoV inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 329.31

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 329.31 Formula

C13H19N3O7

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 2349386-89-4 -- Storage of Stock Solutions

Synonyms MK-4482 Smiles CC(C)C(=O)OCC1C(C(C(O1)N2C=CC(=NC2=O)NO)O)O

Solubility

In vitro
Batch:

DMSO : 66 mg/mL (200.41 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 22 mg/mL

Water : 20 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
SARS-CoV-2 [1]
MERS-CoV [1]
SARS-CoV [1]
In vitro

Molnupiravir (EIDD-2801) is an orally bioavailable NHC-prodrug. This compound is potently antiviral against SARS-CoV-2, MERS-CoV and SARS-CoV in primary human epithelial cell cultures without cytotoxicity. It is effective against remdesivir (RDV)-resistant virus and multiple distinct zoonotic CoV. Its antiviral activity is associated with increased viral mutation rates.[1]

In vivo

Molnupiravir (EIDD-2801) is efficiently hydrolyzed in vivo after absorption, resulting in detection of only free NHC in plasma.[2]

This compound is potently antiviral against SARS-CoV in vivo but the degree of clinical benefit is dependent on the time of initiation post-infection. It robustly reduces MERS-CoV infectious titers, viral RNA, and pathogenesis under both prophylactic and early therapeutic conditions.[1]

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04405739 Completed
SARS-CoV 2
Ridgeback Biotherapeutics LP|Merck Sharp & Dohme LLC
June 16 2020 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.